We have shown previously that the inter-domain interaction between the two domains of RyR (ryanodine receptor), CaMBD [CaM (calmodulin)-binding domain] and CaMLD (CaM-like domain), activates the Ca 2 + channel, and this process is called activation-link formation [Gangopadhyay and Ikemoto (2008) Biochem. J. 411, [415][416][417][418][419][420][421][422][423]. Thus CaM that is bound to CaMBD is expected to interfere the activation-link formation, thereby stabilizing the closed state of the channel under normal conditions. In the present paper, we report that, upon stimulation of neonatal cardiomyocytes with the pro-hypertrophy agonist ET-1 (endothelin-1), CaM dissociates from the RyR, which induces a series of intracellular events: increased frequency of Ca 2 + transients, translocation of the signalling molecules CaM, CaMKII (CaM kinase II) and the transcription factor NFAT (nuclear factor of activated T-cells) to the nucleus. These events then lead to the development of hypertrophy. Importantly, an antiCaMBD antibody that interferes with activation-link formation prevented all of these intracellular events triggered by ET-1 and prevented the development of hypertrophy. These results indicate that the aberrant formation of the activation link between CaMBD and CaMLD of RyR is a key step in the development of hypertrophy in cultured cardiomyocytes.
INTRODUCTION
In RyR2 [cardiac RyR (ryanodine receptor)], CaM (calmodulin) inhibits channel activity at both low (sub-micromolar) and high (micromolar) [Ca 2 + ] [1,2]. CaM binding seems to take place with residues 3583-3603 of RyR2, designated as the CaMBD (CaM-binding domain) [3] . Previous studies on RyR1 (skeletal muscle RyR) have revealed another important segment (amino acids 4064-4210 of RyR1) that resembles the structure of CaM and contains putative Ca 2 + -binding sites [4, 5] . A homologous segment (amino acids 4020-4166) is present in RyR2, which we designate as the CaMLD (CaM-like domain). Our previous studies on RyR1 [6] suggest that inter-domain interaction between CaMBD and CaMLD activates the Ca 2 + channel. To facilitate discussion, we have designated this phenomenon as activationlink formation. According to this model, CaM that is bound with CaMBD is expected to interfere with activation-link formation and block channel activation. This mechanism accounts for the aforementioned fact that bound CaM inhibits channel activity of RyR2, which would help to maintain the closed state of the RyR2 Ca 2 + channel in the diastolic phase and facilitate relaxation in the post-systolic phase.
In many different types of cardiac disease, the RyR2 Ca 2 + channel opens erroneously in an otherwise resting state; a common syndrome known as 'diastolic Ca 2 + leak' [7] [8] [9] . Several reports have suggested that defects in the CaM interaction with RyR2 becomes a pathogenic factor in heart disease. For instance, Meissner and co-workers [10] have reported that transgenic mice containing RyR2 with a mutated CaMBD are unable to bind CaM, developed hypertrophy and had an early death. Ono et al. [11] analysed the RyR2-CaM interaction in normal hearts and in the ventricular pacing-induced canine heart failure model with a fluorescent photoaffinity CaM probe, and have shown that the CaM affinity for RyR2 in the failing hearts is significantly lower than that with RyR2 in normal hearts. Furthermore, Xu et al. [12] have shown, that upon β-adrenergic stimulation of transgenic mice carrying the CPVT (catecholaminergic polymorphic ventricular tachycardia) R2474S mutation in RyR2, the affinity of CaM binding to the CPVT RyR2 was reduced considerably with no appreciable change in WT (wild-type) RyR2.
The findings described above suggest the hypothesis that, in cardiomyocytes under pathological conditions, an abnormally tight activation link is formed between CaMBD and CaMLD, resulting in a weakening of CaM binding and eventual CaM dissociation from RyR2, which in turn induces pathogenic diastolic Ca 2 + leak. The main aim of the present study was to test this hypothesis using neonatal cardiomyocytes as a cell model of hypertrophy. Neurohormonal stimulation of neonatal cardiomyocytes causes hypertrophic growth within 1 day, showing characteristic changes in gene expression [13] [14] [15] [16] and in protein signalling [17] [18] [19] . This makes this system a versatile cell model to study various intracellular molecular events during the course of the development of hypertrophy. In our recent studies [20, 21] , we have induced hypertrophy in neonatal rat cardiomyocytes by ET-1 (endothelin-1), as well as by direct manipulation of the inter-domain interaction between the N-terminal domain and the central domain of RyR2 with a domain peptide, DPc10, corresponding to the central domain of RyR2. We then found that, during the development of hypertrophy, CaM and CaMKII (CaM kinase II) were translocated to the nucleus. CaM translocation coincides with a moderate increase in the frequency of spontaneous Ca 2 + transients, whereas CaMKII translocation coincides with an appearance of the 'trains' of spontaneous Ca transients. These findings suggest that neurohormonal stimulation induces conformational disorders in RyR2, which cause aberrant cytoplasmic Ca 2 + events; the patterns of aberrant Ca 2 + events are registered in the CaM/CaMKII system. This message is then transmitted to the nucleus as a pathogenic signal to develop hypertrophy.
In the present paper, we report that hypertrophic stimulation of neonatal cardiomyocytes with ET-1 produces CaM dissociation from RyR2, which leads to sequential intracellular events, including increased frequency of spontaneous Ca 2 + transients, and translocation of CaM, CaMKII and NFAT (nuclear factor of activated T-cells) to the nucleus. Importantly, we have found that an anti-CaMBD antibody, used as a 'molecular wedge' of the CaMBD-CaMLD interaction, prevented all of these ET-1-induced pathological intracellular events and prevented the development of hypertrophy. This supports the hypothesis that aberrant formation of the channel activation link between CaMBD and CaMLD of RyR2 is an early key event leading to the development of hypertrophy in this cell model.
EXPERIMENTAL

Isolation of primary cardiomyocytes and the induction of hypertrophy by ET-1
Neonatal cardiomyocytes were prepared using a Percoll density gradient method as described previously [13] . Myocytes from 1-2-day-old Sprague-Dawley rat hearts were cultured in a serum-containing medium (Dulbecco's modified Eagle's medium, 10 % horse serum, 5 % fetal bovine serum, 1 unit/ml penicillin, 0.1 mg/ml streptomycin, 0.25 mg/ml amphotericin B, 0.1 mM bromodeoxyuridine and 2 mM L-glutamine) for 24 h. Cardiomyocytes were cultured for another 24 h in a serumfree Dulbecco's modified Eagle's medium containing 0.5 % nutridoma. At this time point, the cells were treated with 0.1 μM ET-1 and then incubated for 24 h for the development of hypertrophy.
The animals used for isolation of the cardiomyocytes were handled following the animal protocol approved by the NIH (National Institutes of Health), and the cells were disposed following the biohazard disposal regulations of the Institute.
In vivo cross-linking assay
Neonatal cardiomyocytes were cultured on fibronectin-coated 10-mm culture dishes with (8-10)×10 6 cells/dish. For in vivo crosslinking, the culture medium was replaced with 2 % formaldehyde in PBS. After incubation for 2 min, the cells were washed with PBS and harvested by scraping the cells off the plate, centrifuged at 10 000 g for 10 min and the cell pellet was suspended in an extraction solution containing 50 mM Tris/HCl (pH 8), 10 mM EGTA and 2 % SDS supplemented with protease inhibitors. Cells were disrupted in a tissue lyser for 1 min with a frequency of 25 Hz/min. After centrifugation, the supernatant was used for Western blot analysis. RyR2 was detected using an anti-RyR2 antibody (34C; 1:200 dilution) and the RyR2-associated CaM was detected with an anti-CaM antibody (1:2000 dilution).
Loading of cardiomyocytes with the anti-CaMBD antibody
The custom-made antibody corresponding to CaMBD of RyR1 was purified using a peptide affinity column [6] . To determine the specificity of the antibody for RyR2, the neonatal cardiomyocyte cell extract was used for Western blot analysis with a 1:15 000 dilution of the antibody. The purified antibody was complexed with a BioPORTER protein-loading agent (Genlantis) for 5 min for its delivery across the cell membrane, and it was added to the serum-free culture medium. After 4 h of incubation, the cells were washed with PBS and the antibody-loaded cells were treated with ET-1 for the development of hypertrophy. The untreated cells were used to check the effect of the antibody alone.
Assay of Ca 2 + transients
Cardiomyocytes were treated with 5 μM fluo 4/AM (fluo 4 acetoxymethyl ester; a cell-permeant Ca 2 + indicator; Invitrogen) in imaging buffer solution (25 mM Hepes, 6 mM glucose, 2 mM CaCl 2 , 150 mM KCl and 1.2 mM MgSO 4 , pH 7.4) and incubated for 30 min at 37
• C. The cells were washed with imaging buffer alone to remove excess fluo 4/AM and then incubated for another 30 min at 37
• C. Live cells were imaged at 22
• C on a confocal microscope (Leica TCS SP5) for synchronous Ca 2 + transients by following the green fluorescence of fluo 4 for 2 min (λ excitation = 494 nm; λ emission = 516 nm).
Immunocytological analysis
Cells fixed with 3.7 % formaldehyde for 15 min were used for immunostaining. Monoclonal anti-CaM (Epitomics) and antiCaMKII (Santa Cruz Biotechnology) antibodies were used for co-immunostaining at a dilution of 1:200. The monoclonal anti-NFAT antibody (Cell Signaling) was used at a 1:100 dilution. The fluorescence intensity in the cytoplasm and the nucleus were quantified using the ImageJ software.
Determination of the cell size
Cells were fixed with 3.7 % formaldehyde for 15 min and immunostained with an anti-(sarcomeric α-actinin) antibody (Sigma). The areas of individual cells in the confocal microscopy images were determined using ImageJ software.
Statistical analysis
Statistical significance was analysed using an unpaired Student's t test with Prism software (GraphPad Software). A P value <0.05 was considered to be statistically significant.
RESULTS
Pro-hypertrophic stimulus of neonatal cardiomyocytes dissociates RyR2-bound CaM
In several animal models of cardiac disease, there is a clear indication of a reduced affinity of CaM binding to RyR2 [11, 12] . It has also been shown that depletion of the ability to bind with CaM from RyR2 causes cardiac hypertrophy and early cardiac death [10] . These facts suggest that the RyR2-bound CaM plays an important role in regulating the normal function of RyR2, and a defective interaction of CaM with RyR2 will cause cardiac disorders. The first question we addressed in the present study was whether CaM dissociates from RyR2 during the development of hypertrophy in neonatal cardiomyocytes. In the experiment shown in Figure 1 , we fixed cardiomyocytes treated with ET-1 and matching control cells at 24 h with 2 % formaldehyde for in vivo protein-protein cross-linking and then subjected the electrophoretically separated proteins to Western blot analysis by immunostaining with the anti-RyR2 and anti-CaM antibodies. The expression level of RyR2 estimated by the immunostaining intensity of RyR2 was approximately identical between the control and ET-1-treated cells. However, the immunostaining intensity of the RyR2-bound CaM in the ET-1-treated cells, expressed as the CaM/RyR2 density ratio, was approximately 30 % that of the control cells. This suggests that neurohormonal stimulation of the cardiomyocytes produced some structural changes (i.e. according to the hypothesis, abnormally tight CaMBD-CaMLD interaction) in RyR2, which decreased the affinity of CaM binding to RyR2 and the partial dissociation of the bound CaM.
Pathological changes in RyR2 induce a series of aberrant intracellular events that lead to the development of hypertrophy
As shown by many investigators, diastolic Ca 2 + leak and intracellular Ca 2 + overload represent pathological states in cardiomyocytes, which are usually recognized as an increased frequency of spontaneous Ca 2 + sparks [22] [23] [24] . In our recent study [21] , we have shown that ET-1 stimulation of neonatal rat cardiomyocytes caused an increased frequency of spontaneous Ca 2 + transients in an early phase and eventually developed into a train of Ca 2 + spikes during the course of the development of hypertrophy. We have also shown that cytoplasmic CaM was translocated into the nucleus in an early phase of hypertrophy development, whereas cytoplasmic CaMKII was translocated into the nucleus at a later phase. Importantly, the translocation of CaM coincided with a moderate increase in the frequency of Ca 2 + transients, and the translocation of CaMKII coincided with the appearance of trains of Ca 2 + spikes. These findings suggested the new concept that the patterns of aberrant intracellular Ca 2 + transients are registered in the CaM/CaMKII system as pathogenic signals, which are transduced to nuclear transcriptional sites to activate the hypertrophy programme as CaM and CaMKII move into the nucleus.
In the present study, we investigated several key events presumably involved in the pathogenic pathway using neonatal cardiomyocytes that had been treated with ET-1 for 24 h with reference to the untreated matching control cells. They are: (i) increased frequency of spontaneous Ca 2 + transients, (ii) translocation of cytoplasmic CaM and CaMKII into the nucleus, (iii) nuclear import of NFAT, one of the most extensively investigated mechanisms in the literature involved in the cytoplasm-to-nucleus transduction of the transcriptional signal to activate the hypertrophy gene programme [18, 19, [25] [26] [27] , and (iv) increase in cell size as an indicator of the development of hypertrophy. In agreement with our previous study [21] , at 24 h of incubation, the ET-1-treated cells showed trains of spontaneous Ca 2 + spikes which were often synchronized among neighbouring cells, whereas there were virtually no spontaneous Ca 2 + transients in the untreated control cells (Figure 2) . Figure 3 shows confocal images of the immunostaining patterns in the control and ET-1-treated cells double-stained with the antiCaM and anti-CaMKII antibodies to show CaM and CaMKII staining. Importantly, in control cells, the staining intensity of both CaM and CaMKII was localized mainly in the cytoplasm, indicating their lower abundance in the nucleus than in the cytoplasm. In the ET-1-treated cells, however, the distribution of the staining density between the cytoplasm and the nucleus was reversed in both CaM and CaMKII, indicating that a large population of both cytoplasmic CaM and CaMKII had moved into the nucleus in the ET-1-treated cells.
Of the various pathogenic mechanisms of cardiac hypertrophy, the mechanism mediated by the nuclear import of NFAT is well established [18, 19, [25] [26] [27] . Namely, Ca 2 + /CaM-mediated activation of calcineurin dephosphorylates the transcriptional factor NFAT and the dephosphorylated NFAT is translocated into the nucleus to activate the hypertrophy programme. In the present study, we performed immunostaining of NFAT in control and ET-1-treated cells using an anti-NFAT antibody. As shown in Figure 4 , the staining intensity was mainly localized in the cytoplasm in untreated cells. In the ET-1-treated and hypertrophied cells, however, the major staining intensity had shifted from the cytoplasm to the nucleus, indicating that, coupled with the aberrant intracellular events described above, NFAT had moved from the cytoplasm to the nucleus. This suggests that the aberrant intracellular events described led to the activation of the hypertrophy gene programme via an NFAT-mediated transcription mechanism. Figure 5 shows morphological evidence that ET-1 treatment and the induced intracellular events described above developed hypertrophy in the neonatal cardiomyocytes. Figure 5(A) shows the cell size distribution of the control and the ET-1-treated and hypertrophied cells at 24 h, with the mean values of the cell sizes shown in Figure 5 (B). ET-1 treatment produced a considerable increase in both the average cell size and variation in the cell size distribution compared with those of the untreated cells.
The anti-CaMBD antibody inhibits the pathological intracellular events and prevents the development of hypertrophy in neonatal cardiomyocytes
According to our hypothesis, partial dissociation of CaM from RyR2 (an event upstream of the series of intracellular events described in the present study) is produced by an abnormally tight interaction between CaMBD and CaMLD, which would have been suppressed by CaMBD-bound CaM (owing to its molecular wedging effect) in a normal diastolic state. A possible way to test this hypothesis might be to introduce a sufficiently large amount of CaM into the cell and to examine whether the exogenously introduced CaM prevented the aberrant intracellular events and the development of hypertrophy. However, this is not a feasible approach, because it is known that overexpression of CaM induces hypertrophy by activating the pro-hypertrophy pathogenic pathways [28, 29] , and the exogenously introduced CaM is expected to affect a variety of cell functions because of its ubiquitous multiple functions [30] [31] [32] . In the present study, we introduced the anti-CaMBD antibody, which is raised against the CaMBD using CaMBP (CaM-binding protein; a synthetic peptide corresponding to the CaMBD of RyR1) as an antigen. RyR1 and RyR2 are highly homologous in their primary structure [33, 34] and, as expected, the anti-CaMBD antibody reacted with RyR2 of neonatal cardiomyocytes (Figure 2 , inset). Our strategy is that the binding of this antibody to CaMBD would block the excessive and abnormal interaction between CaMBD and CaMLD, as the CaMBD-bound CaM would do under normal conditions.
We introduced the anti-CaMBD antibody into the control and ET-1-treated neonatal cardiomyocytes by using the protein carrier BioPORTER [20, 21] , and examined its effect on each of the pathogenic intracellular events and hypertrophic growth of the cells described above. As shown in Figures 2-5 , the introduced antibody inhibited all of these events [i.e. frequent spontaneous Ca 2 + transients (Figure 2 ), nuclear translocation of CaM and CaMKII (Figure 3 ) and nuclear import of NFAT (Figure 4) ], and prevented the development of hypertrophic growth ( Figure 5 ). The antibody had no effect on the untreated control cells (Figures 2-5 ), and non-immune serum had no effect on the ET-1-treated cells (results not shown). These results provide strong support to the notion that the abnormal activation-link formation between CaMBD and CaMLD within RyR2, which must be prevented in normal channel regulation in a resting/diastolic state, is a causative mechanism for the development of hypertrophy in neonatal cardiomyocytes. have shown that, at physiological (micromolar) concentrations of Mg 2 + , the Ca 2 + -dependent CaMBD-CaMLD interaction was inhibited [6] . Importantly, the Ca 2 + -dependent activation and Mg 2 + -dependent inhibition of the CaMBD-CaMLD interaction was closely paralleled by the Ca 2 + -dependent activation and Mg 2 + -dependent inhibition of RyR1 channel activity respectively. These results suggest that the mode of interaction between CaMBD and CaMLD serves as a key mechanism in the conformation-dependent regulation of Ca 2 + channel function. Since RyR2 and RyR1 share a homologous primary structure [36] [37] [38] and a common Ca 2 + -dependent channel activation and Mg 2 + -dependent channel inhibition mechanism, it seems that the same CaMBD-CaMLD interaction-based mechanism may operate in the regulation of RyR2 Ca 2 + channels, as discussed below. In RyR2, CaM inhibits channel activity at both diastolic (nanomolar to sub-micromolar) and systolic (micromolar to submillimolar) cytoplasmic [Ca 2 + ] [1,2]. In the light of the activationlink hypothesis described above, it indicates that CaM which is bound to CaMBD of RyR2 interferes with the CaMBD-CaMLD interaction. Thus, under conditions that prevail in the diastolic phase, namely at sub-threshold [Ca 2 + ] (nanomolar to submicromolar) and in the presence of a physiological concentration of Mg 2 + (1 mM), RyR2-bound CaM will prevent activation-link formation to stabilize the closed state of RyR2 Ca 2 + channels. At above-threshold [Ca 2 + ] (in the systolic phase), RyR2-bound CaM will prevent excessive channel activation (buffering effect) and facilitate post-systolic relaxation.
A common syndrome underlying many different types of cardiac disease is that the RyR2 Ca 2 + channel opens erroneously in an otherwise resting state: the pathological state of RyR2 known as 'diastolic Ca 2 + leak'. It is also known that, in pathological conditions, the threshold concentration of cytoplasmic Ca 2 + for channel activation is considerably reduced, i.e. increased sensitivity to the channel activating Ca 2 + and the threshold concentration of the cytoplasmic Mg 2 + for channel inhibition is considerably increased, that is reduced sensitivity to the inhibitory Mg 2 + [39, 40] . According to the hypothesis described above, such pathological states are produced by two mutually related mechanisms: an increase in Ca 2 + affinity of Ca 2 + -dependent formation of the activation link, and a reduction in Mg 2 + affinity immunostained with the monoclonal anti-NFAT antibody. Scale bar, 25 μm. Right-hand panel, summary of densitometric analysis of the distribution of immunostaining intensity between the cytoplasm and the nucleus as determined using the ImageJ program. The immunostaining intensity of NFAT shifted from the cytoplasm to the nucleus in the ET-1-treated and hypertrophied cells, and the anti-CaMBD antibody incorporated into the cells prevented this effect, indicating that the nuclear import of NFAT, a well-established mechanism of the pathogenesis of cardiac hypertrophy in in vivo models and human patients, is also used as a pathogenic mechanism of hypertrophic growth in neonatal cardiomyocytes.
of Mg 2 + inhibition of the activation-link formation. The aberrant formation of the activation link produced by these mechanisms will weaken CaM binding. Such conditions will result in a sustained de-stabilization of the closed state of the channel, causing sustained diastolic Ca 2 + leak, which ultimately leads to the development of various cardiac disorders, as shown in recent studies. Thus, according to the studies by Xu et al. [12] in the transgenic mice carrying the CPVT R2474S/ + mutation in RyR2 , β-adrenergic stimulation of RyR2 (mimicry of catecholaminergic stimulation that causes lethal arrhythmia) induced a significant reduction in the affinity of CaM binding to the CPVT RyR2, as determined by assaying the binding of a fluorescent photoaffinity CaM probe, CaM-SANPAH. Similar fluorescent photoaffinity CaM-binding assays in the ventricular pacing-induced canine heart failure model described by Ono et al. [11] have shown that, in RyR2 in failing hearts, the CaM affinity is approximately 20 % of that of RyR2 in normal hearts. Furthermore, according to an earlier study by Meissner and co-workers [10] , transgenic mice containing RyR2 unable to bind CaM developed hypertrophy and early death. All of these reports are consistent with the view that the weakened CaMRyR2 interaction and eventual dissociation of CaM from the RyR2 produces various types of cardiac disease, including CPVT, cardiac hypertrophy and heart failure.
Aberrant activation-link formation, weakened CaM binding and eventual CaM dissociation will cause a series of intracellular events that ultimately lead to the development of cardiac disease. Prevention of aberrant activation-link formation will then prevent the pathological events and the development of cardiac disorders. In order to test this prediction, we have employed an in vitro cell model of cardiac hypertrophy. Neurohormonal stimulation of cultured neonatal cardiomyocytes causes hypertrophy, and characteristic changes in gene expression [13] [14] [15] [16] and in protein signalling [17] [18] [19] . The strong advantage of this cellular disease model is that, because of the rather rapid development of disease states, it is possible to investigate various intracellular events during the process of hypertrophy development in a relatively short time. In addition, we have made an important improvement to this system by creating the ability to introduce various key peptides and antibodies into the living cell using a protein carrier. These added abilities have permitted us to manipulate the conformational states of RyR2 to induce and prevent hypertrophy. Thus, as shown in our recent studies [20, 21] , the pharmacological agonist of hypertrophy ET-1, as well as DPc10 (a central domain peptide that causes aberrant inter-domain interaction between the N-terminal domain and the central domain of RyR2), induced hypertrophy, and dantrolene, which corrects the aberrant N-terminal domain/central domain interaction, prevented the development of ET-1-or peptide-induced hypertrophy. In our more recent study in the neonatal cardiomyocyte model, we have shown that, during the ET-1-induced development of hypertrophy, the frequency of spontaneous Ca 2 + transients increases causing cytoplasm-to-nucleus translocation of CaM and CaMKII [21] . These findings suggest that a hypertrophic stimulus applied to the cell-surface receptor first produces a conformational malregulation of RyR2, and aberrant activation of RyR2 Ca 2 + channels and aberrant intracellular Ca 2 + events, and then the pathogenic signal elicited in RyR2 is transduced to the nuclear transcriptional sites via the nuclear translocation of signalling proteins such as CaM and CaMKII.
The present study has shed more light into the sequential intracellular molecular events during the development of hypertrophy in neonatal cardiomyocytes. As shown in the present study, several prominent intracellular events are induced by ET-1, such as (i) a partial dissociation of CaM from RyR2, (ii) a significant increase in the frequency of spontaneous Ca 2 + transients, (iii) nuclear translocation of cytoplasmic CaM, (iv) nuclear translocation of cytoplasmic CaMKII, and (v) import of NFAT into the nucleus. We postulate that a prohypertrophic stimulus applied to the cell-surface receptor first produces an abnormal formation of the activation-link between CaMBD and CaMLD, weakening CaM binding to RyR2 and dissociating the RyR2-bound CaM. This leads to diastolic Ca 2 + leak, which is reflected by the increased frequency of spontaneous Ca 2 + transients. The pattern of aberrant cytoplasmic Ca 2 + events produced by conformational disorders in RyR2 is sensed and memorized by the CaM/CaMKII system. This message is then transmitted to the nucleus as a pathogenic signal when CaM and then CaMKII move into the nucleus for the development of hypertrophy. This process is mediated by the wellknown calcineurin-mediated pro-hypertrophic signal transduction pathway. In this pathway, Ca 2 + /CaM-dependent activation of calcineurin dephosphorylates NFAT, which thereby translocates dephosphorylated NFAT to the nucleus to activate a hypertrophy gene programme [18, 19, [25] [26] [27] . In view of the well-established mechanism of CaMKII/HDAC (histone deacetylase)-mediated activation of the pro-hypertrophic/pro-heart failure programme [17] , we postulate that the observed nuclear translocation of CaMKII may be involved in this pathogenic route.
One of the most important aspects of the present study is the finding that the antibody directed to CaMBD inhibited all of the sequential events described above from (i) to (v), and prevented the development of hypertrophy. This indicates that binding of the antibody to CaMBD produces a 'molecular wedging' effect on the CaMBD-CaMLD interaction and prevented aberrant activation-link formation in the diastolic phase. Consequently, it prevented the subsequent events that would have led to the development of hypertrophy. Thus the results in the present study provide strong evidence that the aberrant activationlink formation between CaMBD and CaMLD is one of early key steps in the signal transduction pathway that eventually leads to the activation of the hypertrophy programme. We should also mention that the aberrant CaMBD-CaMLD interaction is a new target for therapeutic treatment and that the prevention of it is a new strategy for developing a method of treatment.
Previous conformational probe studies of RyR1 and RyR2 in normal and diseased states by Yamamoto and Ikemoto [41] have shown that the tight interaction ('zipping') between the N-terminal domain and the central domain of RyR stabilizes the closed state of the channel, whereas unzipping of the interacting domains opens the channel. In diseased conditions, aberrant domain unzipping takes place in an otherwise resting state [42, 43] . Interestingly, therefore, it seems that the pathological formation of the CaMBD-CaMLD activation link described in the present study and the previously described aberrant unzipping of the interacting N-terminal domain/central domain pair are allosterically coupled. If this is the case, therapeutic agents that correct either aberrant formation of the CaMBD-CaMLD activation link or aberrant unzipping of the N-terminal/central domain pair will be equally effective, and combined application of the two types of therapeutic agents will produce synergetic effects. In support of this concept, dantrolene, which binds to the N-terminal domain [44] and corrects aberrant unzipping of the N-terminal/central domain pair, inhibited diastolic Ca 2 + leak and nuclear translocation of CaM and CaMKII, and then prevented the development of hypertrophy in ET-1-treated neonatal rat cardiomyocytes [21] . In the presence of added CaM, dantrolene exerted a more potent channel inhibition effect [45] .
In conclusion, the antibody, which is directed to CaMBD and has an wedging effect on the CaMBD-CaMLD interaction within RyR2, inhibited pathogenic intracellular events, such as cytoplasmic Ca 2 + overload, nuclear translocation of the putative pathogenic signal transducing proteins (CaM and CaMKII) and nuclear import of NFAT, and prevented the development of hypertrophy in neonatal cardiomyocytes. This supports the notion that an aberrant tight interaction between CaMBD and CaMLD of RyR2 is a key pathogenic mechanism occurring in an early step of the pathogenic pathways of cardiac hypertrophy. An important question to be addressed in future research is whether a similar mechanism operates in the development of cardiac hypertrophy in human patients and animal models.
